Why You Can’t Build a Medtech Start-Up Without Publicity: Interview with Peter Vranes, CEO of Nutromics

Medsider: Learn from MedTech and HealthTech Experts

In this episode of Medsider Radio, we caught up with chemical engineer and serial entrepreneur Peter Vranes, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.

Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.

In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies and the reason he never stops raising money.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Peter if you'd rather read it instead.